Progressive Multifocal Leukoencephalopathy
1
Pipeline Programs
1
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
BiogenCAMBRIDGE, MA
4 programs1
mefloquinePhase 1/21 trial
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal LeukoencephalopathyN/A1 trial
JC Virus Reactivation in Multiple SclerosisN/A1 trial
TysabriN/A1 trial
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Biogenmefloquine
BiogenTysabri
BiogenGenetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
BiogenJC Virus Reactivation in Multiple Sclerosis
Clinical Trials (4)
Total enrollment: 80,438 patients across 4 trials
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
Start: Jan 2009Est. completion: Nov 201037 patients
Phase 1/2Terminated
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
Start: Jun 2017Est. completion: Dec 202380,327 patients
N/ACompleted
NCT01211639BiogenGenetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
Start: Oct 2010Est. completion: Aug 201424 patients
N/ATerminated
JC Virus Reactivation in Multiple Sclerosis
Start: Oct 2010Est. completion: Jan 201650 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space